Rare cancer synovial sarcoma reduced using plasma-activated medium
Method’s anticancer effects verified at cellular and organismal levels without obvious side effects
2025-05-01
(Press-News.org)
Plasma-activated medium (PAM) shows tumor-fighting effects against the rare form of cancer known as synovial sarcoma, an Osaka Metropolitan University-led research team has found.
The group irradiated a mammalian cell culture medium with non-thermal atmospheric-pressure plasma to produce PAM and conducted in vitro tests using human cells and in vivo tests using mice with this type of soft tissue sarcoma.
Graduate School of Medicine student Hana Yao, Associate Professor Hiromitsu Toyoda, and Professor Hiroaki Nakamura, and Graduate School of Engineering Professor Jun-Seok Oh were part of the team that verified the effects of PAM on synovial sarcoma.
Human synovial sarcoma cells exposed to PAM prepared with 5 minutes of plasma irradiation had only a 21% survival rate compared to the control. In mice with this form of cancer, daily injections of PAM around the tumor for four weeks resulted in the reduction of the tumor volume to approximately 46% and final tumor weight to about 59% compared to the control group.
“Not only do our results indicate that PAM has anticancer effects on synovial sarcoma at the cellular and organismal levels, but there also were no obvious side effects such as weight loss or poor appetite observed in the mice,” stated Professor Toyoda. “We aim to further develop our studies using PAM and introduce a new treatment option for synovial sarcoma.”
The results were published in Biomedicines.
###
About OMU
Established in Osaka as one of the largest public universities in Japan, Osaka Metropolitan University is committed to shaping the future of society through “Convergence of Knowledge” and the promotion of world-class research. For more research news, visit https://www.omu.ac.jp/en/ and follow us on social media: X, Facebook, Instagram, LinkedIn.
END
ELSE PRESS RELEASES FROM THIS DATE:
2025-05-01
LOS ANGELES — Keck Hospital of USC earned an “A” Hospital Safety Grade from The Leapfrog Group, an independent national nonprofit watchdog focused on patient safety.
This is the 10th “A” grade the hospital has received since 2019.
“The Leapfrog Group is one of the most trusted names in health care, and it is a tremendous achievement to once again receive the highest safety grade possible,” said Marty Sargeant, MBA, CEO of Keck Medical Center of USC, which includes Keck Hospital.
Leapfrog assigns a letter grade to general hospitals across the country ...
2025-04-30
Treatment with gabapentinoids - drugs such as gabapentin and pregabalin - is not directly associated with an increased risk of self-harm, finds a UK study published by The BMJ today.
However, rates of self-harm were higher before and shortly after treatment, highlighting the need for close monitoring of patients throughout their treatment journey, say the researchers.
Gabapentinoids are prescribed for conditions such as epilepsy, nerve pain, and anxiety disorders.
Previous studies have raised concerns about ...
2025-04-30
‘No-touch’ vein harvesting significantly reduces the risk of graft failure up to three years after coronary artery bypass surgery compared with conventionally harvested vein grafts, finds a study from China published by The BMJ today.
The no-touch technique also translates into meaningful clinical benefits for patients, such as lower rates of heart attacks and need for repeat revascularisation (a procedure to restore blood flow to blocked veins), say the researchers.
A coronary artery bypass graft (CABG) is a surgical procedure used to improve blood flow and oxygen supply to the heart in patients with coronary heart disease. It involves grafting a healthy ...
2025-04-30
GLOBAL: Australian researchers have discovered that a single mutation in the DNA sequence for a methylation enzyme dysregulates key tumour-suppressing pathways, opening up new avenues for blood cancer treatment.
The findings of this research confirm mutant DNA methyltransferase 3A (DNMT3A) as a potential target for effective blood cancer treatment.
One of the most common DNA mutations found in blood cancers is in the sequence encoding DNMT3A. Between 20 and 25% of adults with acute myeloid leukaemia (AML) have mutant DNMT3A.1 This ...
2025-04-30
ChatGPT vs students: study reveals who writes better (and it’s not the AI)
AI generated essays don’t yet live up to the efforts of real students - according to new research from the University of East Anglia (UK).
A new study published today compared the work of 145 real students with essays generated by ChatGPT.
While the AI essays were found to be impressively coherent and grammatically sound, they fell short in one crucial area – they lacked a personal touch.
As the line between human and machine writing ...
2025-04-30
Semaglutide effectively treats liver disease in two thirds of patients, new research has found.
Results from the ESSENCE phase 3 clinical trial published today in the New England Journal of Medicine shows treating patients with the substance can halt and even reverse the disease.
The placebo-controlled outcome trial of participants with a life-threatening form of liver disease known as Metabolic dysfunction associated steatohepatitis (MASH) was conducted at 253 clinical sites across 37 countries around the world. This is the first regulatory-level trial showing the benefit ...
2025-04-30
An investigational gene therapy has successfully restored immune function in all nine children treated with the rare and life-threatening immune disorder called severe leukocyte adhesion deficiency-I, or LAD-I, in an international clinical trial co-led by UCLA.
LAD-I is a genetic condition that affects approximately one in a million people in the world. It is caused by mutations in the gene that produces CD18, a protein that enables white blood cells to travel from the bloodstream to infection sites. In the absence of this critical protein, individuals with severe LAD-I — most of whom are diagnosed within ...
2025-04-30
EMBARGOED FOR RELEASE
5 PM EDT, APRIL 30
CONTACT: A.J. Hostetler
VCU Stravitz-Sanyal Institute for Liver Disease and Metabolic Health
Phone: 804-543-8656 (cell)
Email: AJ.Hostetler@vcuhealth.org
VCU-led research highlights semaglutide’s potential for treating fatty liver disease
International study shows drug reverses liver damage in patients.
RICHMOND, Va. (April 30, 2025) – An international study led by the director of Virginia Commonwealth University’s liver institute suggests that the substance in Ozempic and Wegovy can halt and even reverse a common liver disease that affects millions worldwide.
Led by Arun Sanyal, M.D., of the Stravitz-Sanyal Institute ...
2025-04-30
MINNEAPOLIS — People whose biological age is higher than their chronological age may be more likely to develop dementia than people whose biological age matches or is lower than their chronological age, according to a study published on April 30, 2025, online in Neurology®, the medical journal of the American Academy of Neurology. Biological age is based on biomarkers of aging such as lung function, blood pressure and cholesterol.
The study does not prove that advanced biological age causes dementia; it only shows an association.
“With the rising impact of dementia around the world, identifying risk factors and implementing preventive ...
2025-04-30
Researchers with the University of Calgary and the Chinese University of Hong Kong (CUHK) led an international collaboration that found inflammatory bowel disease (IBD) progresses through four predictable epidemiological stages as it spreads globally. Published in Nature, the study forecasts a major rise in IBD prevalence in Canada by 2045. Researchers say pinpointing where each region sits on the trajectory gives health-care systems a clear roadmap for anticipating and managing IBD today and in the decades to follow.
“Our analysis draws on a century worth of historical epidemiologic data. The findings enable health authorities ...
LAST 30 PRESS RELEASES:
[Press-News.org] Rare cancer synovial sarcoma reduced using plasma-activated medium
Method’s anticancer effects verified at cellular and organismal levels without obvious side effects
